Pharm-Olam International Announces Record Expansion in 2006

HOUSTON, TEXAS. Pharm-Olam International Ltd. (POI), a multi-national, full service CRO to pharmaceutical, biotech, and medical device industries achieved record growth in several areas in 2006, including revenue and geographic coverage in addition to expansion of services.

In 2006 POI was awarded contracts with an aggregate value over $85 million across several therapeutic areas, resulting in the largest year of growth in the history of the company. “While a large portion comes from sponsors we have worked with in the past, we have been approached by many new sponsors who are struggling with recruitment on existing studies”, said Iain Gordon, Director of Global Business Development. “Pharm-Olam has a proven track record of rescuing studies owing to our intimate knowledge of emerging markets where recruitment and retention rates are consistently higher.”

POI continues to expand its global reach by adding local offices in Brazil, Argentina, and South Africa. “Our previous success conducting trials for our sponsors in these countries made establishing permanent offices there a logical choice”, said Gordon. “Pharm-Olam now has coverage comparable to global CRO, but is better positioned to offer sponsors a more responsive partner and greater operational efficiency.”

POI expanded data management and biostatistics services for sponsors by adding Dr. Anthony Orlando, Ph.D. as Vice President of its Global Data Division. Dr. Orlando has over 30 years of data management experience including roles in pharmaceutical companies, the National Center for Toxicological Research/FDA, and contract research organizations.

For further information about Pharm-Olam please contact Iain Gordon at iain.gordon@pharm-olam.com .

About Pharm-Olam International

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.